The operating model presented here is derived using a structured qualitative cross-case synthesis informed by thematic analysis methodology (Braun & Clarke, 2006; Eisenhardt, 1989) and implementation-science approaches to sociotechnical systems. The study adopts a qualitative analytical approach focused on identifying recurring operational patterns rather than estimating causal effects.

Case definition and inclusion criteria: A deployment was defined as a clinical AI system that was actively integrated into clinical workflows (not retrospective only), operated within a regulated or governed healthcare environment, and had progressed beyond initial pilot into operational use with monitoring or oversight mechanisms in place. Deployments remaining in pilot or proof-of-concept stage were excluded.

Sample selection: A total of 12 deployments spanning 2016 to 2024 were included based on three criteria: exposure to multiple lifecycle stages (deployment and monitoring), representation across diagnostic, clinical decision support, and predictive AI systems, and variation in regulatory context (FDA SaMD, EU MDR, and institutional governance). Case identification drew on the author's direct operational access across participant-observer and advisory roles; no systematic search of external databases was conducted, and the sample is accordingly purposive rather than representative.

Data sources: Sources included implementation records, lifecycle and monitoring artifacts, audit and regulatory-readiness documentation, and incident and escalation logs. No patient-level data were accessed or analyzed.

Analytical method: A six-phase thematic synthesis was conducted following Braun and Clarke (2006): familiarization with deployment artifacts; initial coding of operational observations; identification of recurring themes; cross-case validation of themes; mapping of dependencies across governance, lifecycle, integration, and feedback dimensions; and synthesis into the four-layer operating model. Patterns were retained only when observed in three or more deployments and associated with consistent operational consequences. The recurrence threshold was set prior to analysis and applied without exception. The four-layer model emerged inductively from the pattern set rather than being imposed a priori. All analytical decisions were documented contemporaneously in operational notes and cross-referenced against the published implementation literature to assess convergent validity.

Bias and limitations: The author acted as a participant-observer across multiple deployments, introducing potential selection bias — the sample may skew toward environments where operating-model discipline was already partially present — and interpretation bias, as the author cannot fully separate analytical from operational judgments. These were mitigated through the cross-case recurrence threshold, alignment with existing literature, and explicit non-causal framing. These mitigations reduce but do not eliminate the limitation; readers should treat the framework as hypothesis-generating and the reported associations as motivating evidence for the independent empirical validation described in Section 7.

Ethics statement: This work does not constitute human-subjects research. No identifiable patient data were used. The analysis is limited to system-level and organizational processes.

These recurring deployment patterns informed both the abstraction of the four-layer operating model and the generalized case anchors presented in Section 5 (Table 1).

This work is best understood as an execution-layer operating model that formalizes how regulatory, technical, and clinical domains are operationally connected through decision rights, lifecycle controls, and escalation mechanisms. The contribution extends beyond synthesis by defining a structured model of operational dependencies that can be empirically tested and implemented across regulated environments.

Five principles underpin the operating model. First, regulation is treated as a design input: traceability, evidence lineage, and post-market monitoring are built into architecture and workflows from the outset, not appended at compliance review. Second, decision rights precede technology: accountability for clinical outcomes, model behavior, and regulatory posture is made explicit before deployment. Third, lifecycle continuity: development through post-market monitoring is managed as a single lifecycle with controlled transitions rather than discrete handoffs. Fourth, economic sustainability: scaling requires reducing manual oversight load and preventing rework cycles. Fifth, global regulatory alignment is treated as an execution concern rather than a structural constraint — by defining governance authority, lifecycle controls, and post-market feedback loops independently of any single regulator's documentation format, the model enables organizations to satisfy divergent regulatory regimes through localized artifacts while preserving a unified operating system, allowing scale across geographies without re-engineering operating capability for each jurisdiction.

Good Machine Learning Practice defines lifecycle principles; this operating model defines the execution mechanisms — governance forums, approvals, escalation thresholds, and operating cadence — through which those principles are enacted. ISO 13485 and ISO 14971 define quality and risk processes; this model embeds them into day-to-day decision making and clinical operations rather than treating them as documentation overlays. MLOps defines technical deployment discipline; this model adds regulatorily defensible change control, clinical accountability, and HITL evolution that clinical settings require.

The operating model comprises four interdependent layers. Layer 1 establishes governance and decision rights, defining who approves deployment and authorizes change. Layer 2 covers technical lifecycle management from development through post-market monitoring. Layer 3 addresses clinical integration with adaptive human-in-the-loop controls that evolve as scale increases. Layer 4 provides continuous performance, risk, and economic feedback loops that link monitoring signals to governance authority and controlled intervention. Figure 1 illustrates how these layers interact as an integrated system.

Governance is operational authority, not policy. It defines who owns clinical outcomes, who approves releases, who can pause or roll back a system, how incidents and drift are escalated, and how audit findings trigger corrective and preventive action (CAPA). Key governance artifacts include a governance charter, role definitions, a RACI map for lifecycle stages, release and change-approval thresholds, and documented escalation timelines. Effective governance separates model-development accountability from clinical-approval accountability, reducing conflicts of interest and improving defensibility. Governance cadence matters: standing forums (weekly operational review, monthly risk and quality review, and quarterly product review) create structured venues for escalation and cross-functional accountability, reducing reliance on ad hoc decision making. Governance also establishes predefined thresholds that trigger review, rollback, or constrained use, limiting ambiguity during incidents or audit pressure.

This layer extends MLOps to meet regulated requirements through controlled development and validation environments, versioned datasets and artifacts, reproducible training, structured verification and validation, and change control aligned to regulatory strategy. Four core components form its foundation. Evidence lineage captures dataset provenance, labeling protocols, observed data shifts, and representativeness analyses. Model lineage records architecture, hyperparameters, training runs, and calibration decisions. Release packages assemble the model card, intended-use statement, contraindications, validation summaries, human-factors notes, monitoring plan, and rollback plan. Post-market change control defines triggers for retraining, revalidation tiers, and the documentation updates required at each tier.

Human-in-the-loop oversight is a lifecycle variable rather than a fixed setting. During pilots, oversight is intentionally high-touch to validate appropriateness and build trust. At early scale, oversight shifts to structured sampling and exception-driven review with defined escalation criteria. At mature scale, HITL becomes targeted: monitoring-driven interventions with periodic audits and review. Embedding HITL in the primary workflow is critical, as parallel review systems create alert fatigue and workarounds. Integration must also address human factors: clarity of recommendations, uncertainty communication, and user feedback loops.

Extension to generative and non-deterministic systems: Generative and large language model (LLM)-based systems introduce additional risk dimensions not typically present in conventional discriminative models, including non-deterministic outputs, probabilistic reasoning chains, and the potential for hallucinated or otherwise unverifiable responses. Within the proposed operating model, these risks are mitigated primarily through governance and lifecycle controls rather than model-level constraints: intended-use definitions are narrowed, human-in-the-loop oversight is elevated from sampling-based review to mandatory gating at defined decision points, and output monitoring focuses on semantic validity, override patterns, and downstream clinical actions. Change control thresholds for generative systems are correspondingly stricter. This reinforces the central thesis: as model behavior becomes less deterministic, organizational operating discipline becomes the primary safety mechanism.

Monitoring must be linked to authority. Performance, safety, fairness, and economic signals are mapped to thresholds and response playbooks. Economic signals — cost of oversight, rework burden, and downtime — must be visible to governance to prevent unsustainable scaling. Feedback loop maturity is the difference between late discovery of drift and structured, preemptive intervention.

Failures map predictably to missing operating layers. Without governance, organizations experience indecision and audit exposure. Without lifecycle control, they accumulate uncontrolled changes and unplanned revalidation. Without integration, they see low adoption and workarounds. Without feedback loops, intervention is delayed and risk compounds. Table 2 summarizes these relationships. Sequencing also matters: governance first, lifecycle management second, integration and HITL design third, and feedback-loop maturation last. Deployments that invert this sequence are consistently associated with higher remediation burden, slower scale transitions, and greater operational risk (Raji et al., 2020; Sculley et al., 2015).

Clinical AI pilots often demonstrate strong technical performance and local clinical acceptance under conditions of informal oversight and close collaboration between clinicians and technical teams. In this case, an AI system was initially deployed within a narrowly scoped pilot addressing a single clinical use case. Validation artifacts were created iteratively, and decisions regarding model updates and usage were made through consensus rather than formal approval structures. These conditions supported rapid iteration but masked structural weaknesses.

As the organization attempted to transition the system into a regulated production environment, operating gaps became apparent. Documentation practices varied across development cycles, evidence lineage was incomplete, and accountability for clinical outcomes versus technical performance was not clearly delineated. Release readiness was assessed primarily through engineering criteria, while regulatory and clinical sign-off processes remained loosely defined. These gaps surfaced during regulatory review, resulting in delayed approval, additional evidence requests, and rework.

Stabilization required changes to the operating model rather than to the underlying algorithm. The organization introduced formal governance structures defining decision rights and escalation pathways, standardized lifecycle documentation, and embedded human-in-the-loop oversight directly into clinical workflows. Approval thresholds and audit-ready artifacts were established before resubmission. Following these changes, the system achieved regulated deployment with greater predictability, reduced remediation cycles, and increased organizational confidence. This case suggests that failure in the transition from pilot to regulated deployment is frequently driven by operating model deficiencies rather than core algorithmic shortcomings (Figure 2).

Following initial regulated deployment, the AI system was expanded across multiple clinical sites with heterogeneous workflows, staffing models, and local governance norms. Although the core model and technical infrastructure remained consistent, operational execution varied significantly: local teams adapted workflows independently, oversight practices diverged, and escalation thresholds were interpreted inconsistently across sites. As scale increased, these variations compounded. Aggregate model-performance metrics remained stable, obscuring underlying operational fragility, and expansion slowed as leadership struggled to reconcile local autonomy with enterprise-level risk and compliance expectations.

Resolution required re-centering the scale-up effort around the operating model rather than the model alone. Central governance defined minimum operating standards, clarified decision rights, and established uniform escalation pathways, while permitting controlled local variation where clinically appropriate. Human-in-the-loop oversight evolved from universal review to structured sampling aligned with site maturity and risk profile, and economic metrics were introduced to surface hidden costs associated with fragmented execution. The key takeaway is that scaling amplifies organizational variance; without a unifying operating model, local adaptations accumulate into systemic inefficiency and risk (Figure 3).

After sustained production use, the clinical AI system entered a period of apparent stability. Over time, subtle performance changes emerged due to shifts in data characteristics, evolving clinical practices, and upstream system modifications (Koch et al., 2024). Concurrently, the organization underwent an external regulatory audit, placing heightened scrutiny on post-market monitoring and change-management practices.

Monitoring infrastructure detected performance drift and variation across subpopulations, but organizational response differed based on operating model maturity. In environments lacking clear decision authority, technical findings prompted extended debate rather than decisive action. Where escalation thresholds and governance pathways were predefined, monitoring signals triggered structured review, documented justification, and controlled intervention. A mature operating model enabled the organization to address drift without halting deployment or initiating emergency remediation: retraining and workflow adjustments were executed through controlled lifecycle processes, and audit inquiries were addressed using existing evidence rather than reactive reconstruction. Predefined escalation thresholds shortened the path from drift detection to corrective action, allowing performance changes to be addressed through structured lifecycle processes before regulatory or clinical escalation became necessary (Figure 4).

Four core artifacts operationalize the governance and lifecycle layers of the model. The governance charter defines scope, membership, decision authority, meeting cadence, quorum rules, and conflict-of-interest provisions. The release-approval checklist verifies evidence-package completeness, clinical sign-off, QA/RA review, the deployment plan, and the rollback plan before any system goes live. Change-control tiers classify updates as minor (documentation only, no revalidation), moderate (limited revalidation, internal approval), or major (full revalidation and updated regulatory submission). The incident-response playbook defines classification criteria, immediate mitigation actions, internal and external communication plans, CAPA initiation protocols, and the post-incident review process.

Conventional accuracy metrics are necessary but not sufficient. The operating model requires parallel tracking across four categories. Safety metrics include false-negative and false-positive rates in clinically meaningful strata, near-miss signals, and override patterns. Operations metrics include review workload per 1,000 cases, time to escalation, time to mitigation, and rollback frequency. Compliance metrics include evidence-package completeness rates, audit-trail coverage, and CAPA cycle time. Economic metrics include cost per deployment episode, cost of oversight per 1,000 cases, remediation cost per incident, and time to measurable clinical value from go-live. Each category is tied to governance thresholds and defined response playbooks.

Escalation thresholds convert monitoring signals into governance decisions. Organizations should calibrate specific values — delta magnitudes, time windows, and consecutive-period criteria — to their clinical context, regulatory environment, and system risk profile. Four signal classes illustrate the mapping. A drift signal (statistically significant shift in key feature distributions sustained over a predefined number of monitoring days) triggers constrained use pending governance review. A performance signal (degradation beyond a predefined delta from validated baseline in one or more critical clinical strata) triggers mandatory governance review and documented justification before continued operation. A workflow signal (clinician override rates exceeding a predefined threshold for two consecutive reporting periods) triggers a workflow-integration review and HITL recalibration. A safety signal (any sentinel event attributable to AI output) triggers immediate governance review, potential deployment pause, and CAPA initiation.

Five role archetypes define the human operating infrastructure of the model, each carrying distinct accountability that cannot be absorbed by an adjacent function without creating governance gaps. The Clinical AI Product Owner defines and maintains intended-use scope, owns clinical outcome targets, and serves as the primary liaison between clinical and technical teams. The AI Quality Lead owns audit-readiness, evidence-package discipline, and the CAPA lifecycle. The ML Platform Lead owns model training pipelines, monitoring infrastructure, and reproducibility controls. Clinical Champions own workflow-fit assessment at each site and serve as first-line escalation for workflow-level concerns. The Governance Chair maintains the integrity of decision-rights allocation and holds final escalation authority and rollback-trigger decision rights.

The operating model generalizes to other regulated AI domains — finance, energy, transportation — where change control, auditability, and accountable decision rights are required. Domain adaptation primarily involves different risk taxonomies and regulatory artifacts; the core structure of governance, lifecycle management, integration, and feedback loops remains consistent. The primary adaptation point in non-healthcare domains is typically the substitution of clinical-workflow integration requirements with domain-specific human-oversight mechanisms appropriate to the consequential decision context.